Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: Systematic review and meta-analysis of imaging studies

British Journal of Psychiatry

Volumn 204, Issue 6, 2014, Pages 420-429

  Kambeitz, Joseph ^a   Abi Dargham, Anissa ^b   Kapur, Shitij ^a   Howes, Oliver D ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER;

BRAIN REGION; CINGULATE GYRUS; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; HUMAN; PREFRONTAL CORTEX; REVIEW; SCHIZOPHRENIA; SUBSTANTIA NIGRA; SYSTEMATIC REVIEW; TEMPORAL CORTEX; THALAMUS; UNCUS; BRAIN; CORPUS STRIATUM; META ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL LOBE;

BRAIN; CORPUS STRIATUM; DOPAMINE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; SCHIZOPHRENIA; TEMPORAL LOBE; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84901857589     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.132308     Document Type: Review

References (94)

1. American Psychiatric Association. APATF on Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. American Psychiatric Publishing, 2000.
2. Lopez AD. Global Burden of Disease and Risk Factors. Oxford University Press, 2006.
3. McGuire P, Howes OD, Stone J, Fusar-Poli P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci 2008; 29: 91-8.
4. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med 2006; 12: 1016-22.
5. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976; 2: 19-76.
6. Van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160: 492-4.
7. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474-86.
8. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 2009; 35: 549-62.
9. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69: 776-86.
10. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004; 7 (suppl 1): S1-5.
11. Wong DF, Wagner Jr HN, Tune LE, Dannals RF, Pearlson GD, Links JM, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558-63.
12. Farde L, Halldin C, Stone-Elander S, Sedvall G. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl) 1987; 92: 278-84.
13. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651-4.
14. Halldin C, Farde L, Högberg T, Mohell N, Hall H, Suhara T, et al. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 1995; 36 : 1275-81.
15. Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, Ouyang X, et al. Preliminary ass essment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol 1999; 26: 519-27.
16. Kessler RM, Mason NS, Votaw JR, De Paulis T, Clanton JA, Ansari MS, et al. Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 1992; 223: 105-7.
17. Martin GE, Williams M, Pettibone DJ, Zrada MM, Lotti VJ, Taylor DA, et al. Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo. J Pharmacol Exp Ther 1985; 233: 395-401.
18. Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem 2006; 13: 2139-53.
19. Sedvall G, Pauli S, Karlsson P, Farde L, Nordström AL, Nyberg S, et al. PET imaging of neuroreceptors in schizophrenia. Eur Neuropsychopharmacol 1995; 5 (suppl): 25-30.
20. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71-6.
21. Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, et al. Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: a PET study with [11 C]NNC112. J Psychopharmacol (Oxford) 2012; 26: 794-805.
22. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci USA 2001; 98: 831-6.
23. The R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2010.
24. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1-48.
25. Champely S. pwr: Basic Functions for Power Analysis. R Package Version 1.1.1. R Project, 2009 (http://CRAN.R-project.org/package&equalspwr).
26. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Academic Press, 1985.
27. Hedges LV, Vevea JL. Fixed-and random-effects models in meta-analysis. Psychol Methods 1998; 3: 486.
28. Raudenbusch S. Analysing effect sizes: random effects models. In The Handbook of Research Synthesis and Meta-Analysis (2nd edn) (eds H Cooper, LV Hedges, JC Valentine): 295-315. Russell Sage Foundation, 2009.
29. Higgins J, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557.
30. Higgings JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Cochrane Collaboration, 2011 (http://handbook. cochrane.org/).
31. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629.
32. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-9.
33. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006; 85: 232-44.
34. Lehrer DS, Christian BT, Kirbas C, Chiang M, Sidhu S, Short H, et al. 18F-fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophr Res 2010; 122: 43-52.
35. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 2004; 161: 1016-22.
36. Yasuno F, Suhara T, Okubo Y, Ichimiya T, Takano A, Sudo Y, et al. Abnormal effective connectivity of dopamine D2 receptor binding in schizophrenia. Psychiatry Res 2005; 138: 197-207.
37. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 2002; 59: 25-30.
38. Talvik M, Nordström A-L, Olsson H, Halldin C, Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 2003; 6: 361-70.
39. Talvik M, Nordström A-L, Okubo Y, Olsson H, Borg J, Halldin C, et al. Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 2006; 148: 165-73.
40. Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, et al. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry 2010; 68: 634-41.
41. Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, et al. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 2006; 60: 621-9.
42. Tuppurainen H, Kuikka JT, Laakso MP, Viinamäki H, Husso M, Tiihonen J. Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256: 382-7.
43. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, et al. The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 2009; 34: 1078-86.
44. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, et al. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009; 65: 1024-31.
45. Tuppurainen H, Kuikka J, Viinamäki H, Husso-Saastamoinen M, Bergström K, Tiihonen J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 2003; 8: 453-5.
46. Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R, et al. Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 2009; 108: 78-84.
47. Lindström LH, Gefvert O, Hagberg G, Lundberg T, Bergström M, Hartvig P, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46: 681-8.
48. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 2000; 100: 1-11.
49. Kumakura Y, Cumming P, Vernaleken I, Buchholz H-G, Siessmeier T, Heinz A, et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci 2007; 27: 8080-7.
50. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-6.
51. Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002; 159: 761-7.
52. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708-19.
53. Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, et al. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res 2009; 43: 1219-23.
54. Guo N, Hwang D-R, Lo E-S, Huang Y-Y, Laruelle M, Abi-Dargham A. Dopamine depletion and in vivo binding of PET D1 receptor radioligands: implications for imaging studies in schizophrenia. Neuropsychopharmacology 2003; 28: 1703-11.
55. Lidow MS, Goldman-Rakic PS. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA 1994; 91: 4353-6.
56. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo N-N, et al. In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 2007; 9: 117-25.
57. Hirvonen J, Johansson J, Teräs M, Oikonen V, Lumme V, Virsu P, et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 2008; 28: 1059-69.
58. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage 2010; 50: 524-31.
59. Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang X-Y, Sangare J, et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 2008; 163: 171-82.
60. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998; 39: 904-11.
61. Kim E, Shidahara M, Tsoumpas C, McGinnity CJ, Kwon JS, Howes OD, et al. Partial volume correction using structural-functional synergistic resolution recovery: comparison with geometric transfer matrix method. J Cereb Blood Flow Metab 2013; 33: 914-20.
62. Fornito A, Yücel M, Patti J, Wood SJ, Pantelis C. Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. Schizophr Res 2009; 108: 104-13.
63. Rousset OG, Collins DL, Rahmim A, Wong DF. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med 2008; 49: 1097-106.
64. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012; 169: 1203-10.
65. Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ, et al. The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev 2009; 33: 1109-32.
66. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-9.
67. Kuwabara H, McCaul ME, Wand GS, Earley CJ, Allen RP, Weerts EM, et al. Dissociative changes in the Bmax and KD of dopamine D2/D3 receptors with aging observed in functional subdivisions of the striatum: a revisit with an improved data analysis method. J Nucl Med 2012; 53: 805-12.
68. Hietala J, Någren K, Lehikoinen P, Ruotsalainen U, Syvälahti E. Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: a test-retest analysis. J Cereb Blood Flow Metab 1999; 19: 210-7.
69. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang D-R, Scher E, et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006; 60: 485-95.
70. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004; 57: 1124-30.
71. Stang A. Low P-values exclude nothing, and P-values are no substitute for measures of effect. J Clin Epidemiol 2011; 64: 452-453; author reply 453.
72. Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, et al. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res 2008; 106: 148-55.
73. Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Grasby PM, McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry 2007; 191 (suppl 51): s13-8.
74. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009; 15: 2550-9.
75. Sánchez-González MA, García-Cabezas MA, Rico B, Cavada C. The primate thalamus is a key target for brain dopamine. J Neurosci 2005; 25: 6076-83.
76. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-40.
77. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-74.
78. Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 13-20.
79. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011; 16: 885-6.
80. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 2012; 71: 561-7.
81. Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, et al. Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain 2013; 136: 3242-51.
82. 11C]FLB 457: reproducibility studies. Synapse 2011; 65: 35-40.
83. Montgomery AJ, Asselin M-C, Farde L, Grasby PM. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET. J Cereb Blood Flow Metab 2007; 27: 369-77.
84. Riccardi P, Li R, Ansari MS, Zald D, Park S, Dawant B, et al. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 2006; 31: 1016-26.
85. Chou YH, Halldin C, Farde L. Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET study. Synapse 2000; 38: 138-43.
86. Mukherjee J, Christian BT, Narayanan TK, Shi B, Collins D. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Res 2005; 1032: 77-84.
87. Slifstein M, Narendran R, Hwang D-R, Sudo Y, Talbot PS, Huang Y, et al. Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: single bolus and bolus plus constant infusion studies. Synapse 2004; 54: 46-63.
88. Aalto S, Brück A, Laine M, Någren K, Rinne JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 2005; 25: 2471-7.
89. Okauchi T, Suhara T, Maeda J, Kawabe K, Obayashi S, Suzuki K. Effect of endogenous dopamine on endogenous dopamine on extrastriated [11C]FLB 457 binding measured by PET. Synapse 2001; 41: 87-95.
90. Tsukada H, Harada N, Nishiyama S, Fukumoto D, Kakiuchi T. Acute NMDA receptor antagonism induces biphasic striatal utilization of L-[beta-11C]DOPA: PET studies in the conscious monkey brain. Synapse 2005; 57: 116-9.
91. Cropley VL, Innis RB, Nathan PJ, Brown AK, Sangare JL, Lerner A, et al. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse 2008; 62: 399-408.
92. Frankle WG, Mason NS, Rabiner EA, Ridler K, May MA, Asmonga D, et al. No effect of dopamine depletion on the binding of the high-affinity D 2/3 radiotracer [11C]FLB 457 in the human cortex. Synapse 2010; 64: 879-85.
93. Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry 2010; 68: 599-602.
94. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G, et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 2011; 108: 1158-63.